Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Transplantation as salvage therapy for high-risk patients with myeloma in relapse

Bone Marrow Transplantation volume 30, pages 873–878 (2002)Cite this article

Abstract

Patients with myeloma relapsing after tandem transplant have a poor survival and treatment options are limited. The role of additional salvage transplant procedures for these patients is unknown. To evaluate the benefit and identify prognostic factors, the outcome of 76 consecutive patients with recurrent myeloma after tandem transplant receiving salvage transplants (ST) was analyzed. Prior to ST, 23 patients (30%) had shown chemosensitive response to preceding salvage chemotherapy: two complete remissions (CR); eight near CRs (nCR: only immunofixation positive); 13 partial remissions (PR ⩾75% reduction in M protein). Fifty received an autologous transplant, 22 a sibling-matched allogeneic transplant, and four a matched-unrelated allogeneic transplant. Overall response after ST was 59%: eight CRs (11%); 14 nCRs (18%); 23 PRs (30%). Overall survival (OS) at 2 years was 19%; 2 year event-free survival rate (EFS) 7%. On univariate analysis for survival, only pre-transplant chemosensitive relapse (P < 0.05), serum albumin >3 g/dl (P = 0.001), normal LDH (P = 0.04), and long interval between the second transplant and relapse/progression were significant beneficial factors. In a Cox proportional hazard model, chemosensitive relapse, and albumin >3 g/dl were significant for better OS: hazard ratio (HR) 1.4, 1.7, respectively, while normal LDH, and absence of CA13 were significant for better EFS: HR 1.8, 1.7, respectively. Patients with albumin >3 g/dl who had chemosensitive disease before ST (n = 16) had a median survival of 16 months, compared to 7 months (n = 34) and 2 months (n = 26) for patients with only one (n = 34) or no favorable prognostic factors (n = 28), respectively (P < 0.001). Their survival at 2 years post-ST was 43%, 17% and 11%, respectively. Our study suggests further transplantation should only be considered in the setting of a clinical trial in patients with favorable prognostic factors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Selby PJ, McElwain TJ, Nandi AC et al. Multiple myeloma treated with high dose intravenous melphalan Br J Haematol 1987 66: 55 62

    Article  CAS  PubMed  Google Scholar 

  2. Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma Blood 1986 67: 1298 1301

    CAS  PubMed  Google Scholar 

  3. Barlogie B, Alexanian R, Dicke KA et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma Blood 1987 70: 869 872

    CAS  PubMed  Google Scholar 

  4. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group Blood 2000 95: 7 11

    CAS  PubMed  Google Scholar 

  5. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome New Engl J Med 1996 335: 91 97

    Article  CAS  PubMed  Google Scholar 

  6. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplant for newly diagnosed multiple myeloma Blood 1999 93: 55 65

    CAS  PubMed  Google Scholar 

  7. Attal M, Harousseau JL . Randomized trial experience of the Intergroupe Francophone du Myelome Semin Hematol 2001 38: 226 230

    Article  CAS  PubMed  Google Scholar 

  8. Fassas A, Tricot G . Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma Semin Hematol 2001 38: 231 242

    Article  CAS  PubMed  Google Scholar 

  9. Tricot G, Jagannath S, Vesole DH et al. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy Bone Marrow Transplant 1995 16: 7 11

    CAS  PubMed  Google Scholar 

  10. Barlogie B, Desikan R, Eddlemon P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients Blood 2001 98: 492 494

    Article  CAS  PubMed  Google Scholar 

  11. Barlogie B, Zangari M, Spencer T et al. Thalidomide in the management of multiple myeloma Semin Hematol 2001 38: 250 259

    Article  CAS  PubMed  Google Scholar 

  12. Hideshima T, Richardson P, Chauhan D et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res 2001 61: 3071 3076

    CAS  PubMed  Google Scholar 

  13. Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 2000 96: 2943 2950

    CAS  PubMed  Google Scholar 

  14. Mansi JL, Cunningham D, Viner C et al. Repeat administration of high dose melphalan in relapsed myeloma Br J Cancer 1993 68: 983 987

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Badros A, Barlogie B, Siegel E et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning J Clin Oncol 2002 20: 1295 1303

    Article  PubMed  Google Scholar 

  16. Gooley TA, Leisenring W, Crowley J et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators Stat Med 1999 18: 695 706

    Article  CAS  PubMed  Google Scholar 

  17. Desikan R, Barlogie B, Sawyer J et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities Blood 2000 95: 4008 4010

    CAS  PubMed  Google Scholar 

  18. Bjorkstrand B . European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma Semin Hematol 2001 38: 219 225

    Article  CAS  PubMed  Google Scholar 

  19. Corradini P, Voena C, Tarella C et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells J Clin Oncol 1999 17: 208 215

    Article  CAS  PubMed  Google Scholar 

  20. Cavo M, Terragna C, Martinelli G et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma Blood 2000 96: 355 357

    CAS  PubMed  Google Scholar 

  21. Bosi A, Laszlo D, Labopin M et al. Acute Leukemia Working Party of the European Blood and Marrow Transplant Group. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation J Clin Oncol 2001 19: 3675 3684

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA

    C-K Lee, B Barlogie, M Zangari, A Fassas, E Anaissie, C Morris, F van Rhee, M Cottler-Fox, R Thertulien, F Muwalla, S Mazher & G Tricot

  2. Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA

    A Badros

Authors
  1. C-K Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Barlogie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Zangari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Fassas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Anaissie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F van Rhee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Cottler-Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Thertulien
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F Muwalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Mazher
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Badros
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. G Tricot
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, CK., Barlogie, B., Zangari, M. et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant 30, 873–878 (2002). https://doi.org/10.1038/sj.bmt.1703715

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703715

Keywords

This article is cited by

Search

Advanced search

Quick links